NOVELTY - Preparing cinacalcet hydrochloride (I) involves hydrogenating (unsaturated cinacalcet hydrochloride (III) in the presence of a hydrogenation catalyst in a solvent to provide the pure cinacalcet hydrochloride (I); or reacting cinacalcet free base (II) with a nitrogen protecting agent in the presence of a base in a first solvent (s1) to provide N-protected cinacalcet of formula (IV), and converting the compound (IV) into pure cinacalcet hydrochloride (I) by reaction with hydrochloric acid in a second solvent (s2).    USE - To treat secondary hyperparathyroidism in patients with chronic kidney disease, hypercalcemia in patients with parathyroid carcinoma.    ADVANTAGE - The process is efficient, convenient, industrially advantageous, environmentally friendly, and provides pure cinacalcet hydrochloride.    DETAILED DESCRIPTION - Preparing cinacalcet hydrochloride (I) involves hydrogenating (unsaturated cinacalcet hydrochloride (III) in the presence of a hydrogenation catalyst in a solvent to provide the pure cinacalcet hydrochloride (I); or reacting cinacalcet free base (II) with a nitrogen protecting agent in the presence of a base in a first solvent (s1) to provide N-protected cinacalcet of formula (IV), and converting the compound (IV) into pure cinacalcet hydrochloride (I) by reaction with hydrochloric acid in a second solvent (s2); or neutralizing compound (III) with a base in a first solvent (s3) to provide (R)- alpha -methyl-N-(3-(3-(trifluoromethyl)phenyl)propylene)-1-naphthalene methaneamine(V), reacting the unsaturated compound (V) with a nitrogen protecting agent in the presence of a base in a second solvent (s4) to provide N-protected unsaturated compound of formula (VI), hydrogenating the compound (VI) in the presence of a hydrogenation catalyst in a third solvent (s5) to provide the N-protected cinacalcet (IV), and converting the compound (IV) into pure cinacalcet hydrochloride (I) by reaction with hydrochloric acid in a fourth solvent (s6).    P1=nitrogen protecting group.    INDEPENDENT CLAIMS are included for the following:    (1) new N-protected cinacalcet compound (IV);    (2) new N-protected unsaturated cinacalcet compound (VI);    (3) new solid state form of a salt of (R)- alpha -methyl-N-(3-(3-(trifluoromethyl)phenyl)propylene)-1-naphthalenemethane amine (unsaturated cinacalcet salt), where the salt of unsaturated cinacalcet is a hydrochloride salt, an oxalate salt or a di-p-toluoyl-L-(+)-tartrate salt;    (4) preparation of unsaturated cinacalcet salt (P1) involving providing a first solution of unsaturated cinacalcet free base in a solvent (s7); combining the first solution with an acid to produce a second solution or suspension containing unsaturated cinacalcet acid addition salt, where the acid is selected from the group consisting of hydrochloric acid, oxalic acid and di-p-toluoyl-L-(+)-tartaric acid; and isolating and/or recovering solid state form of unsaturated cinacalcet salt from the second solution or suspension.